Ligand Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
Ligand Pharmaceuticals Robust financial performance driven by full year 2025 royalty revenue growth of Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “We delivered strong fourth quarter results, exceeding our initial full-year adjusted EPS guidance by approximately 30%. This growth was driven by better-than-expected performance across several products in our royalty portfolio, including the successful out-licensing and partner launch of Zelsuvmi. The
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals (LGND) had its price target raised by Oppenheimer Holdings, Inc. from $275.00 to $277.00. They now have an "outperform" rating on the stock.MarketBeat
- Ligand Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Ligand Pharma (LGND) Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ligand: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Ligand Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 2/26/26 - Form 8-K
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LGND's page on the SEC website